Wyeth Researchers Honored by American Chemical Society for Pioneering Contributions to Medicinal Chemistry
News Aug 22, 2007
Wyeth Pharmaceuticals has announced that four researchers in the Company’s Chemical and Screening Sciences group were honored with awards presented at the 234th American Chemical Society National Meeting & Exposition in Boston this week:
• Andrew Fensome, Ph.D., Principal Research Scientist II, received the prestigious David W. Robertson Award for Excellence in Medicinal Chemistry, which recognizes the outstanding contributions of young scientists that shape this field. As a contributing investigator on numerous studies of nonsteroidal progesterone receptor modulators, Dr. Fensome’s work on the development of nonsteroidal oral contraceptive agents has resulted in seven drug candidates that have advanced into development.
• Edmund I. Graziani, Ph.D., Principal Research Scientist II, received the Young Industrial Investigators Award for significant achievement, contributions and innovation, and outstanding promise for future contributions to organic chemistry. The award is given to scientists with no more than 10 years of experience since graduate school or postdoctoral appointment.
• Biqi Wu, M.S., Senior Research Scientist I, and Kevin Curran, B.A., Senior Research Scientist I, will each receive a Technical Achievement in Organic Chemistry (TAOC) Award. This award represents significant achievement and contributions to organic chemistry and is given to highly productive and creative BS/MS chemists.
“The recognition of these four scientists reflects the high quality of work being done throughout Wyeth Research, particularly in our chemistry group,” says Magid Abou-Gharbia, Ph.D., Senior Vice President of Chemical and Screening Sciences at Wyeth Research.
“Medicinal chemistry is one of the key components of our drug discovery efforts and has resulted in many important drug candidates. We are very proud of our colleagues who have been honored and are excited for their continued contribution to cutting-edge research and the subsequent contributions to global health care.”
Presented by the ACS Division of Medicinal Chemistry, the David W. Robertson Award for Excellence in Medicinal Chemistry was created in 2005 in memory of David W. Robertson, a medicinal chemist at Pfizer Global Research and Development.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE